Publication Author: Basu_Anirban

• Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment.

  Kim DD, Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ. Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. Pharmacoeconomics. 2019 Oct 21. doi: 10.1007/s40273-019-0084

  rakerr2

  October 21, 2019

• Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.

  Brouwer ED, Basu A, Yeung K. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013. Pharmacoeconomics. 2019 Oct;37(10):1287-1300. doi: 10.1007/s40273-019-00821-5.

  rakerr2

  October 1, 2019

• Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration.

  Bounthavong M, Devine EB, Christopher MLD, Harvey MA, Veenstra DL, Basu A. Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. Health Serv Res. 2019 Oct;54(5):1055-1064. doi:

  rakerr2

  October 1, 2019

• Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study.

  Regier DA, Veenstra DL, Basu A, Carlson JJ. Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study. Pharmacoeconomics. 2019 Sep 6. doi: 10.1007/s40273-019-00834-0. [Epub ahead of print]

  rakerr2

  September 6, 2019

• Postdischarge Unplanned Care Events Among Commercially Insured Patients With an Observation Stay Versus Short Inpatient Admission.

  Sabbatini AK, Wright B, Kocher K, Hall MK, Basu A. Postdischarge Unplanned Care Events Among Commercially Insured Patients With an Observation Stay Versus Short Inpatient Admission. Ann Emerg Med. 2018 Nov 20. pii: S0196-0644(18)31330-1. doi: 10.1016/j.an

  rakerr2

  September 1, 2019

• Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

  Guzauskas GF, Basu A, Carlson JJ, Veenstra DL. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. Value Health. 2019 Sep;22(9):988-994. doi:

  rakerr2

  September 1, 2019

• Time Horizons in Cost Analyses-Reply.

  Basu A, Maciejewski ML. Time Horizons in Cost Analyses-Reply. JAMA. 2019 Aug 13;322(6):582-583. doi: 10.1001/jama.2019.7861.

  rakerr2

  August 13, 2019

• Medicare expenditures attributable to dementia.

  White L, Fishman P, Basu A, Crane PK, Larson EB, Coe NB. Medicare expenditures attributable to dementia. Health Serv Res. 2019 Aug;54(4):773-781. doi: 10.1111/1475-6773.13134. Epub 2019 Mar 13.

  rakerr2

  August 1, 2019

• Do cancer treatments have option value? Real-world evidence from metastatic melanoma.

  Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Econ. 2019 Jul;28(7):855-867. doi: 10.1002/hec.3899.

  rakerr2

  July 1, 2019

• How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.

  Li M, Basu A, Bennette C, Veenstra D, Garrison LP Jr. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value Health. 2019 Jul;22(7):777-784. doi: 10.1016/j.jval.2019.02.002. Epub

  rakerr2

  July 1, 2019